LitAlert ~~ GeneLit.com

    • Evaluating mismatch repair status to screen clinical advanced breast carcinomas for immunotherapy: experience from a large academic institution.
    • Arole V, Shafi S, Challa B, Parwani AV, Tozbikian G, Li Z.
    • Clin Breast Cancer. 2022 Jan 21:S1526-8209(22)00022-2. doi: 10.1016/j.clbc.2022.01.010. Epub ahead of print.
    • 11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.
    • van Halteren HK, Tan A, Pellegrino B, Brasiuniene B, Bennouna J, Cunquero-Tomás AJ, Strijbos M; ESMO Practicing Oncologists Working Group.
    • ESMO Open. 2022 Jan 17;7(1):100376. doi: 10.1016/j.esmoop.2021.100376. Epub ahead of print.
    • Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    • Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.
    • Eur J Med Chem. 2022 Jan 12;230:114109. doi: 10.1016/j.ejmech.2022.114109. Epub ahead of print.
    • Review
    • Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells.
    • Loke J, Alim I, Yam S, Klugman S, Xia LC, Gruber D, Tegay D, LaBella A, Onel K, Ostrer H.
    • HGG Adv. 2022 Jan 7;100085. doi: 10.1016/j.xhgg.2022.100085. Epub ahead of print.
    • Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
    • Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S.
    • Cancer Treat Rev. 2022 Jan 5;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub ahead of print.